NEW YORK (GenomeWeb News) — Illumina today said first-quarter revenues increased 148 percent as R&D spending nearly doubled and the company posted a $300 million net loss affected by acquisition-related charges.
 
Total receipts for the three months ended March 31 increased to $72.2 million from $29.1 million year over year.
 
Product revenues nearly tripled, rising to $61.2 million from $21.3 million, while service and other revenue more than doubled to $10.8 million from $5.2 million year over year.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.